|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
EXAS Analysis & Videos »
EXAS: Bull or Bear?
New Index of Cancer Diagnostic and Therapeutic Stocks
EXAS
|
|
|
+150.00%
in
85 days
By Mike Havrilla on 4/12/09 at BioMedReports.com The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632. <> A World Health Organization report released last year es...
|
BioMed Stock Movers: DNDN, EXAS, KG
EXAS
|
|
|
-7.56%
in
20 hours
(closed on 04/09/09)
Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation. The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the Company's fate. <> <> <>http://biomedreports.com/article...
|
EXACT Sciences Forms Pact with Genzyme
EXAS
|
|
|
-40.83%
in
49 days
(closed on 03/18/09)
EXACT Sciences Forms Pact with Genzyme After the market close, EXACT Sciences announced that it formed a strategic pact with Genzyme (GENZ), which represents the grounds for the Board's refusal two weeks ago in response to Sequenom's (SQNM) hostile exchange offer at $1.50 per share in stock. The announcement followed news in the pre-market today that SQNM planned to commence its exchange offer through 3/24/09, valuing EXAS at $41M. <> However, the GENZ deal included the pur...
|
Healthcare Hot Spots Beyond Stem Cells
EXAS
|
|
|
+14.18%
in
2 days
(closed on 01/28/09)
Beyond Stem Cells: Healthcare Hot Spots With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). <> Below are three additional areas and associated companies for investors to consider in the search of the next hot s...
|
New Preventive Medicine Index
EXAS
|
|
|
-0.66%
in
1 day
(closed on 01/26/09)
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together. <> With the focus on preven...
|
Create Your Own Diagnostics ETF
EXAS
|
|
|
+7.97%
in
5 days
(closed on 01/25/09)
Create Your Own Diagnostics ETF <> With HealthShares closing shop at year-end , including the former Diagnostics fund, investors who are interested in the space can create their own ETF comprised of companies from the ETF Innovators Preventive Medicine and Emerging Diagnostics Indexes. Below is a list of companies which have stocks listed for trading in the U.S. at over $1/share with a market cap of less than $10B, focusing on smaller companies which are more leveraged to diagnostics and represent possible takeover targets for larger players such as Roche (...
|
EXACT Sciences Rejects Sequenom's $41M Offer
EXAS
|
|
|
-8.00%
in
8 days
(closed on 01/20/09)
<> Since I profiled EXACT Sciences (EXAS) in late December as part of the ETF Innovators Emerging Diagnostics Index , EXAS announced that its stool-based DNA [sDNA] screening test was added to the colorectal cancer screening options in 12 more states + Washington DC and the Company received an unsolicited, all-stock buyout offer from Sequenom (SQNM) after the market close on Friday, which is valued at $41M or $1.50 per share.
It has not been an easy ride for EXAS since I first wrote about the Company in October 2007, ...
|
EXACT
EXAS
|
|
|
+0.00%
in
1 minute
(closed on 01/12/09)
<> Since I profiled EXACT Sciences (EXAS) in late December as part of the ETF Innovators Emerging Diagnostics Index , EXAS announced that its stool-based DNA [sDNA] screening test was added to the colorectal cancer screening options in 12 more states + Washington DC and the Company received an unsolicited, all-stock buyout offer from Sequenom (SQNM) after the market close on Friday, which is valued at $41M or $1.50 per share.
It has not been an easy ride for EXAS since I first wrote about the Company in October 2007, ...
|
Analyzing Sequenom's Offer for EXACT Sciences
EXAS
|
|
|
-0.66%
in
5 hours
(closed on 01/12/09)
<> Since I profiled EXACT Sciences (EXAS) in late December as part of the ETF Innovators Emerging Diagnostics Index , EXAS announced that its stool-based DNA [sDNA] screening test was added to the colorectal cancer screening options in 12 more states + Washington DC and the Company received an unsolicited, all-stock buyout offer from Sequenom (SQNM) after the market close on Friday, which is valued at $41M or $1.50 per share.
It has not been an easy ride for EXAS since I first wrote about the Company in October 2007, ...
|
EXACT Sciences Next Generation Stool-Based DNA Technology Outperforms Blood Plasma Testing
EXAS
|
|
|
-35.29%
in
140 days
(closed on 12/26/08)
EXACT Sciences (EXAS) announced the published results of a study in which stool and blood plasma were compared head-to-head for the detection of colorectal cancer [CRC] using an improved BEAMing DNA detection technology from Johns Hopkins University. Study results demonstrated 92% sensitivity for detecting CRC in stool samples, which outperformed blood plasma testing -- especially in the detection of early stage disease.
In the study, a total of 25 stool DNA [sDNA] samples from colorectal cancer patients were analyzed and a next generation sDNA technology correctly identified 23 (92%...
|
ColoSure & Cost Reductions Key to EXACT's Future
EXAS
|
|
|
+19.70%
in
20 days
(closed on 08/08/08)
 EXACT Sciences (EXAS) recently announced plans to implement a cost reduction strategy, which includes suspending a clinical validation study of its V2 DNA-based colorectal cancer [CRC] screening technology, eliminating eight jobs, and renegotiating fixed commitments. The Company expects these initiatives will fund operations through at least 2Q09 based on current liquidity, without the need to raise capital at currently depressed market prices for the stock. EXACT's partner LabCorp (LH) has recently launched a single-marker, lab-based fecal DNA test (based on the Vimentin gene which ...
|
A New Strategy for EXACT Sciences
EXAS
+68.79%
in
364 days
<>Despite a key endorsement by the American Cancer Society for EXACT Science's (EXAS) stool DNA-based colorectal cancer screening test earlier this year, the stock continues to languish at multi-year lows on light average volumes. EXACT is expected to finalize its FDA protocol for the V2 technology of its test to gain the agency's approval and also engaged Leerink Swan to explore strategic alternatives over three months ago. In April , the Company submitted its pre-IDE study protocol to the FDA for a de novo 510(k) filing of its V2 technology. I expect the FDA protocol to be finalized soon, r...
|
BEAMing Profits at Exact Biosciences
EXAS
|
|
|
-8.62%
in
656 days
Exact Sciences has licensed a PCR miniaturization technology developed by Bert Vogelstein of Johns Hopkins Kimmel Cancer Center; this tech is capable of counting each individual fragment that is amplified thereby eliminating false positives. The company will apply this technology to tests that will determine genetic predisposition to certain cancers. I like nearly each and every small, innovative diagnostics company at this point in time due to the consolidation currently going on this space; Roche alone has acquired genomics/diagnostics companies over the last year. With the rights to ...
|
People Bullish on EXAS
People Bearish on EXAS
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on EXAS |
Be the first to start a discussion and earn 2 points.
More Resources
|
About EXACT Sciences Corp.
- Answers.com
